Gemtuzumab(CMA-676) is a monoclonal antibody directed against the CD33 antigen and consists of a recombinant humanized IgG4 antibody.Gemtuzumab can be used to synthesize Gemtuzumab ozogamicin, an antibody coupled compound (ADC) Gemtuzumab is used in the study of acute myeloid leukemia.

Samrotamab (PR-1498487) is a humanized anti-LRRC15 antibody that can be used to synthesize the ADC compound (Samrotamab vedotin).

Rovalpituzumab is a humanized monoclonal antibody targeting delta-like protein 3 (DLL3) and is utilized to synthesize antibody-active molecule conjugates (ADCs). It exhibits anticancer activity and is used in the treatment of small cell lung cancer (SCLC).

Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody that is a naked antibody to the ADC compound Losatuxizumab vedotin, with potential anti-tumor activity for the study of advanced malignant solid tumors.

Vadastuximab (Anti-Human CD33 Recombinant Antibody) is a humanized anti-CD33 monoclonal antibody that can be used for the synthesis of the ADC compound Vadastuximab talirine and for the study of acute myeloid leukemia (AML).

Naratuximab (Anti-TSPAN26/CD37 Reference Antibody) is a humanized monoclonal antibody against CD37 that can be used to synthesize the ADC compound Naratuximab emtansine.

Turmetabart is an IgG1 monoclonal antibody targeting SEZ6, which can be used for the synthesis of antibody-drug conjugates (ADCs), such as ABBV-011.

Cofetuzumab (PF-06523435) is a monoclonal antibody targeting protein tyrosine kinase 7 (PTK7). It can be used to synthesize the ADC compound cofetuzumab pelidotin.

Iladatuzumab (MCDS0593A) is a monoclonal antibody targeting CD79B and is a naked antibody to the ADC compound Iladatuzumab vedotin, which has potential anticancer activity for the study of B-cell non-Hodgkin's lymphoma (B-NHL).

Idactamab (INT-001) is a monoclonal antibody to the human amino acid transport protein ASCT2. Idactamab can be used to prepare ADC MEDI7247.

LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ZIP6.LadiratuzumAb is a naked antibody to SGN-LIV1A and is capable of synthesizing an antibody-activated molecule coupling (ADC), SGN-LIV1A.LadiratuzumAb can be used for the prevention and treatment of breast cancer.

Disitamab Vedotin (RC48-0) is a humanized monoclonal antibody that targets HER2 and can be utilized in creating antibody-drug conjugates (ADCs), specifically referred to as Disitamab Vedotin [1].

Puxitatug (INT-016) is a humanised monoclonal antibody targeting VTCN1/B7H4, commonly used as the targeting component of the antibody-drug conjugate (ADC) Puxitatug samrotecan, delivering the drug specifically to cancer cells expressing B7-H4.

Anti-EFNA4 Antibody (PF-06647263 Naked Antibody) is a monoclonal antibody targeting EFNA4 and can be used for the synthesis of the ADC PF-06647263.

Anti-ETBR Antibody (DEDN6526A Naked Antibody) is a highly specific monoclonal antibody targeting the endothelin B receptor (ETBR) and serves as the antibody for the ADC molecule DEDN6526A. DEDN6526A (RG-7636) is a humanized ETBR-targeting antibody-drug conjugate developed for melanoma research.

Sigvotatug Vedotin is an antibody-drug conjugate (ADC) designed to selectively target integrin αvβ6-positive tumor cells through an engineered antibody with high specificity. Sigvotatug Vedotin employs a protease-cleavable linker that delivers the cytotoxic payload monomethyl auristatin E (MMAE), a microtubule inhibitor, directly into tumor cells. Upon internalization, MMAE disrupts microtubule organization, inhibits proper cell division, and ultimately results in tumor cell death, providing a targeted strategy in oncology research.

Coltuximab is a humanized anti-CD19 antibody that can be used to synthesize ADC compounds (Coltuximab Ravtansine).

Vobramitamab (AEX-4089) is a humanized monoclonal antibody (mAb) targeting the B7-H3 antigen (CD276) which is conjugated to the prodrug seco-duocarmycin hydroxybenzamide azaindole (seco-DUBA) through a enzymatically cleavable peptide-based linker, thereby creating the investigational antibody-drug conjugate (ADC) known as MGC018.

Pinatuzumab is a humanised monoclonal antibody targeting CD22, commonly used to synthesise the ADC molecule Pinatuzumab vedotin, which is employed in the study of B-cell malignancies such as non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia (CLL).

Moxetumomab is a monoclonal antibody targeting CD22, which can be used to synthesise the antibody-drug conjugate (ADC) Moxetumomab pasudotox for the study of hairy cell leukaemia (HCL).

Denintuzumab (hBU 12) is a humanized monoclonal antibody targeting CD19, used in the synthesis of ADC compound Denintuzumab Mafodotin and in the study of acute lymphoblastic leukemia.

Ozuriftamab (BA302) is a human immunoglobulin IgG1 kappa monoclonal antibody specifically designed to target the receptor tyrosine kinase-like orphan receptor 2 (ROR2), and this antibody serves as the foundational targeting moiety for the synthesis of antibody-drug conjugates (ADCs), such as Ozuriftamab vedotin.

Sofituzumab is a humanised monoclonal antibody targeting the MUC16 protein, commonly used in the synthetic ADC Sofituzumab vedotin, which can be used to treat ovarian cancer and pancreatic cancer.

Cantuzumab is a monoclonal antibody targeting the CanAg antigen with anti-tumor activity, used in the synthesis of the ADC compound cantuzumab mertansine.